Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 14Gastrointestinal 7Head & Neck 3Genitourinary 3Sarcoma 2Tumor-Agnostic 1Other solid neoplasm 1Gynecologic 1Endocrine 1Breast 1

Conditions

Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Osteosarcoma 1Osteonecrosis 1Osteomyelitis 1Chondrosarcoma 1Bone Neoplasms 1

Interventions

Radiotherapy 216Cyclophosphamide 211Doxorubicin 207Temozolomide 181Ifosfamide 121Filgrastim 111Etoposide 101Imatinib Mesylate 99Vincristine 92Gemcitabine 89Bevacizumab 83Magnetic Resonance Spectroscopy 79Irinotecan 79pembrolizumab 75Radiation 67Carboplatin 65pazopanib 60Methotrexate 60Nivolumab 58Cisplatin 58fludarabine phosphate 56Peripheral Blood Stem Cell Transplantation 56Specimen Handling 53Docetaxel 50Busulfan 48Trabectedin 47Biopsy 47Melphalan 46Surgical Procedures, Operative 45Paclitaxel 44

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Ferrosoferric Oxide × Sarcoma × Clear all
NCT01336803 2023-12-27

Osteosarcoma

Stanford University

Phase 2 Completed
32 enrolled 11 charts
Sarcoma

Bone Neoplasms, Chondrosarcoma, Osteomyelitis, Osteonecrosis, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma

NCT01663090 2020-10-19

Ferumoxytol-Enhanced MRI in Adult/Pedi Sarcomas

Dana-Farber Cancer Institute

Phase NA Withdrawn
Sarcoma

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡